Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
13 sept. 2022 08h30 HE
|
Biofrontera Inc.
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
16 mai 2022 08h00 HE
|
Biofrontera Inc.
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor...
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting
17 mars 2022 11h20 HE
|
Biofrontera Inc.
Company to have a strong onsite presence at the world’s largest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend WOBURN, Mass., March 17,...
Biofrontera Inc. Announces Closing of $15 Million Private Placement
01 déc. 2021 19h05 HE
|
Biofrontera Inc.
WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
29 nov. 2021 09h27 HE
|
Biofrontera Inc.
WOBURN, MA., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), today announced today that it has entered into a securities purchase agreement with a single institutional...
Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
23 oct. 2019 02h00 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with...
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
25 mars 2019 10h00 HE
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
20 mars 2019 10h50 HE
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...
Biofrontera reports earnings results for the third quarter and first nine months of 2018
16 nov. 2018 02h20 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results
05 nov. 2018 06h26 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...